Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 - Seite 2

Phase III JAVELIN Head and Neck 100 (Presentation #910O). Primary results from
this Phase III study will be presented. The study is a demonstration of our
commitment to develop options for patients with squamous cell carcinoma of the
head and neck, and the results increase understanding in the field of the role
of immunotherapy.

Tepotinib Phase II VISION

(Presentations: #1283P; 1286P; 1347P). Three posters from the largest study in
patients with non-small cell lung cancer (NSCLC) harboring MET ex14 skipping
treated with tepotinib-an oral, once-daily, highly-selective MET inhibitor. Data
presented will highlight:

- Durable clinical activity that has been consistent across clinically relevant
subgroups both in treatment-naïve and in previously treated patients as well
as in patients with brain metastases as assessed by liquid biopsy or tissue
biopsy (Poster #1283P)
- Health-related quality of life (HRQOL) has shown to be maintained, with
clinically meaningful delays in the time to deterioration of cough, dyspnea,
and chest pain (Poster #1286P)
- A safety profile consisting of mostly mild-to-moderate adverse events with few
treatment discontinuations.

INSIGHT 2 (NSCLC) : The INSIGHT 2 study assessing the combination of osimertinib
and tepotinib in patients with EGFR-mutant NSCLC that has developed resistance
to first-line osimertinib treatment due to MET amplification is ongoing and
actively recruiting patients (Poster #1415TiP).

Bintrafusp alfa (M7824)

Data from the INTR@PID clinical trial program for first-in-class bintrafusp
alfa, an investigational bifunctional fusion protein, targeting both TGF-? and
PD-L1 pathways, shows promising and durable responses across multiple tumor
types including NSCLC and biliary tract cancer (BTC) with a manageable safety
profile in Phase I expansion cohorts.

Two long-term follow-up studies assessing efficacy and safety from the INTR@PID
clinical trial program will be presented as posters at ESMO 2020:

- INTR@PID Solid Tumor 001 three-year long-term follow-up for 2L treatment of
NSCLC (Poster #1272P)
- INTR@PID Solid Tumor 008 28-month long-term follow-up in patients with
pretreated biliary tract cancer (Poster #73P)

In addition, preliminary analysis will be presented in a mini-oral presentation
(#616MO) from a trial conducted by the National Cancer Institute (NCI), the
Quick Efficacy Seeking Trial (QuEST), investigating a triple combination therapy
(BN-brachyury [BVax] + bintrafusp alfa + N-803) in castration-resistant prostate